(Q41484084)

1 October 2017

1 reference

title

Drug-drug interactions in pediatric psychopharmacology (English)

1 reference

1 October 2017

0 references

Ten Eick AP

1

1 reference

1 October 2017

Nakamura H

series ordinal

2

1 reference

1 October 2017

Reed MD

series ordinal

3

1 reference

1 October 2017

publication date

1 October 1998

1 reference

Pediatric Clinics of North America

1 October 2017

published in

1 reference

1 October 2017

volume

45

1 reference

1 October 2017

issue

5

1 reference

1 October 2017

page(s)

1233-64, x-xi

1 reference

Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Impairment of hepatic drug oxidation by propoxyphene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The Antagonism of Amphetamine-Induced Symptomatology by a Neuroleptic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Nefazodone-induced carbamazepine toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Elevated antidepressant plasma levels after addition of fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Metabolic drug-drug interactions: perspective from FDA medical and clinical pharmacology reviewers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

SSRI and sympathominetic interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Cisapride. Drug interactions of clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interactions between sympathomimetic amines and antidepressant agents in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A toxic reaction from combining fluoxetine and phentermine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Potentiation of amphetamine and pethidine by monoamineoxidase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interaction between Clonidine and Desipramine in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Combined drug therapy of chronic schizophrenics. Controlled evaluation of placebo, dextro-amphetamine, imipiramine, isocarboxazid and trifluoperazine added to maintenance doses of chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Anticholinergic side effects of trazodone combined with another pharmacologic agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Lithium Carbonate, Haloperidol, and Irreversible Brain Damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Concomitant imipramine and methylphenidate administration: a case report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Comparison of the effects of hydrochlorothiazide and furosemide on lithium disposition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

DEATH ASSOCIATED WITH TRANYLCYPROMINE AND CHEESE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Status epilepticus associated with the combination of valproic acid and clomipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Heart block in a patient on propranolol and fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Buspirone: review of its pharmacology and current perspectives on its mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Amphetamine poisoning. Effectiveness of chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Methylphenidate antagonism of haloperidol, interaction with cholinergic and anticholinergic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Chlorpromazine: a study of its action on the circulation in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Severe hypotension associated with concurrent clonidine and antipsychotic medication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Isoniazid, meperidine, and hypotension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Methylphenidate Interaction With Both Anticonvulsants and Ethyl Biscoumacetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Possible phenytoin-methylphenidate interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

SSRI and sympathomimetic interaction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Seizure associated with fluoxetine and adjuvant buspirone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clinical pharmacokinetics of nefazodone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clinical importance of the interaction of diazepam and cimetidine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fluoxetine impairs clearance of alprazolam but not of clonazepam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Increased carbamazepine plasma concentrations after fluoxetine coadministration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Role of cytochrome P450 enzymes in drug-drug interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Different pharmacological interaction of clonidine and guanabenz with antidepressive drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Mania resulting from lithium-fluoxetine combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Diazepam/beta-adrenoceptor antagonist interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Apparent interaction between nefazodone and cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Cimetidine interaction with imipramine and nortriptyline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Adjustment of lithium dose during lithium-chlorothiazide therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The effects of intravenous theophylline infusion versus intravenous sodium bicarbonate infusion on lithium clearance in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Medical use of psychostimulants: an overview.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Use of levodopa with other drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Antagonism of Guanethidine by Chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The Question of Lithium/Neuroleptic Toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The influence of steady-state ciprofloxacin on the pharmacokinetics and pharmacodynamics of a single dose of diazepam in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Possible interaction between an MAOI and "ecstasy"

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Lithium and non-steroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Cross-tapering clozapine and risperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Severe Hyperpyrexia Due to Tranylcypromine-Amphetamine Toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Effect of methylphenidate on plasma anticonvulsant levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A clinical study of mechanisms of action of chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Influence of lansoprazole treatment on diazepam plasma concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

DEATH AFTER COMBINED DEXAMPHETAMINE AND PHENELZINE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Overview: pharmacokinetic drug-drug interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

FATAL REACTION TO PHENELZINE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clinically significant interactions of psychotropic agents with antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Drug interactions: effect of methylphenidate on the disposition of diphenylhydantoin in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

FAILURE OF DEXTROAMPHETAMINE SULFATE TO INFLUENCE EATING AND SLEEPING PATTERNS IN OBESE SCHIZOPHRENIC PATIENTS: CLINICAL AND PHARMACOLOGICAL SIGNIFICANCE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Possible toxicity of combined fluoxetine and lithium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

PICKLED HERRING AND TRANYLCYPROMINE REACTION.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Drug interactions with guanethidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Diazepam interaction with antituberculosis drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Serotonin syndrome induced by fluvoxamine-lithium interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A potentially hazardous interaction between erythromycin and midazolam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Lithium in migraine and cluster headache: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Theophylline precipitated alterations of lithium clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Neurotoxicity with combined administration of lithium and a neuroleptic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fatality associated with combined fluoxetine-amitriptyline therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Case report: interaction of rifampin and nortriptyline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Drug-drug interactions and the cytochrome P450 system: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Amitriptyline and asymptomatic hypoglycemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Lithium-carbamazepine neurotoxicity and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Elevation of thioridazine plasma levels by propranolol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interaction of benzodiazepines with tricyclic antidepressants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Letter: Cocaine , amphetamine, and tricyclic antidepressants and synaptic transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A case of MAO inhibitor/MDMA interaction: agony after ecstasy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Serotonin syndrome caused by a moclobemide-clomipramine interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Carbamazepine coadministration with fluoxetine or fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Clinically significant pharmacokinetic drug interactions with carbamazepine. An update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Double-blind placebo-controlled trial of lithium in episodic cluster headache

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Toxic reaction following the combined administration of fluoxetine and L-tryptophan: five case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interaction of fluoxetine and selegiline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

The influence of a tricyclic antidepressive agent (protriptyline) on some of the circulatory effects of noradrenaline and adrenaline in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Potential terfenadine-fluoxetine interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Paradoxical reaction to buspirone augmentation of fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Pharmacokinetic interaction between risperidone and clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Ketorolac (Toradol) induced lithium toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Inhibition of propranolol metabolism by chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Interaction of metoprolol and fluoxetine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

7 January 2021

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

7 January 2021

Seizure following addition of erythromycin to clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

7 January 2021

Suspected adverse methylphenidate-imipramine interactions in children

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

7 January 2021

Reversal of some therapeutic effects of an antipsychotic agent by an antiparkinsonism drug

1 reference

https://api.crossref.org/works/10.1016%2FS0031-3955%2805%2970071-7

7 January 2021

10.1016/S0031-3955(05)70071-7

Identifiers

DOI

1 reference

1 October 2017

1 reference